Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

Related

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026

Vinge advises Spotlight Group in connection with offer from Kriptown

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026